Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2025-01-28 00:00:00 ET · period of report 2025-01-24 · accession 0001737287-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-28 | 2025-01-24 | ALLO | Chang David D | Pres, CEO, Dir | A - Grant | $0.00 | +552.2K | 5.36M | +11% | $0 |
| D | 2025-01-28 | 2025-01-24 | ALLO | Chang David D | Pres, CEO, Dir | A - Grant | $0.00 | +1.95M | 1.95M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-24 | A | A | 552,174 | $0.00 | 5,363,240 | D | — | — | (F1) Includes 960 shares of the Issuer's common stock acquired by the reporting person on September 15, 2024 pursuant to an employee stock purchase program. |
| 2 | Derivative | Stock Option (Right to buy) | 2025-01-24 | A | A | 1,952,130 | $0.00 | 1,952,130 | D | $1.94 · — to 2035-01-24 | 1,952,130 Common Stock | (F5) 25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter. |